CClinicalTrials.gg
WithdrawnNCT05182216Updated Jan 6, 2023

Social Media Use in Sickle Cell Patients

An observational study in Survey, Family Life, sponsored by University of Alabama at Birmingham. Withdrawn. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-06.

Sponsored by University of Alabama at Birmingham · Observational

Why this study was withdrawn
We have withdrawn this study.
Study type
Observational
Model
Ecologic or community
Time perspective
Cross-sectional
Enrollment
0
Ages
18 Years and older
Sex
All
01

Study summary

Surveys of patients to identify primary social media sources for health news.

02

Conditions studied

  • Survey, Family Life
03

In context

Lead sponsor

University of Alabama at Birmingham is the lead sponsor of 1,396 studies on the registry; 284 are open to participants now.

Of its 156 completed or terminated interventional studies of FDA-regulated products, 124 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Adults with diagnosis of sickle cell disease

Inclusion criteria

  • sickle cell disease diagnosis

Exclusion criteria

Exclusion Criteria:

  • negative sickle cell disease diagnosis
05

Study design

Observational model
Ecologic or community
Time perspective
Cross-sectional
Enrollment
0 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Social Media Use in Sickle Cell Patients

    Surveys. The survey will have a variety of social media options and ask participants to select the medium used to receive information on health, news, and entertainment.

    Time frame: six months

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05182216
Lead sponsor
University of Alabama at Birmingham
Responsible party
Sonja Smith (Program Manager, University of Alabama at Birmingham) — Principal investigator
First posted
Jan 10, 2022
Start date
Jan 1, 2023 (estimated)
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Jan 6, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion